Cinven is reviewing strategic options for laboratory-services company Synlab International GmbH including a potential sale, people with knowledge of the matter said.
The private equity firm has been speaking with potential advisers and could start a sale process early next year, the people said, asking not to be identified because the information is private. Cinven plans to seek a valuation of about 5.5 billion euros ($6 billion) including debt for Augsburg, Germany-based Synlab, one of the people said.
A sale of Synlab would likely attract other private equity firms, the people said. No final decision has been made, and Cinven could elect to keep the business, the people said. A spokeswoman for Cinven declined to comment, while Synlab didn’t answer phone calls seeking comment.
Cinven first invested in Synlab in June 2015, buying a majority stake from fellow private equity firm BC Partners for about 1.7 billion euros, Bloomberg News reported at the time. It combined the business with Labco SA, which it agreed to buy earlier that year for 1.2 billion euros.
Synlab, led by Chief Executive Officer Mathieu Floreani, also counts Novo A/S and Ontario Teachers’ Pension Plan as minority investors, according to its website. It operates across more than 40 countries, handling more than 500 million clinical tests annually, according to Synlab’s website.
Cinven also owns stakes in retailer Kurt Geiger and German drugmaker Stada Arzneimittel AG, according to its website.
The sale plan comes at a time when Cinven’s rival Apax Partners is also weighing a sale of diagnostic services business Unilabs. The buyout firm is working with advisers at Rothschild & Co. to look at options for the business, people familiar with the matter said last week.
Source: Bloomberg
Can’t stop reading? Read more
Carlyle explores £600m sale of UK fintech leader Calastone
Carlyle, the US private equity giant managing $447bn in assets, is considering selling Calastone, a UK-based funds network and data company. The potential sale, managed by Barclays, could value Calastone at over £600m, or more than 20 times its EBITDA, based on...
NYSCRF boosts private markets investments by $3.3bn, strengthening alternatives strategy
The $275bn New York State Common Retirement Fund committed $3.3bn to private markets, bringing its alternatives exposure to nearly $100bn. Private equity makes up 14.45% of the portfolio, with real assets and real estate at 13.32% and credit strategies at 8%. These...
Florida-based Palm Peak Capital acquires Pacific Shoring in first investment deal
Palm Peak Capital, a private equity firm launched in 2024 by former Sun Capital Partners executives, has acquired California-based Pacific Shoring Products. This acquisition marks Palm Peak’s first investment and reflects its focus on high-potential industrial...